TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement
Filipa C. Lynce, Kaoru Shimada, Claudine J. Isaacs, Xue Geng, Edward T. Richardson, Adam Nelson, Candace Bavette Mainor, Mei Wei, Julie Marie Collins, Paula Raffin Pohlmann, Arielle Lutterman Heeke, Kelly F Zheng, Madeline G Townsend, Nicole Swanson, Lauren M. Sloat, , Jennifer L. Guerriero
The paper shows BRCA-mutant breast cancers respond to PARP inhibitors with immune remodeling, but PD-L1 blockade is ineffective due to spatial separation of PD-L1+ cells and PD-1+ T cells.
bioRxiv · Sep 18, 2026 · PreprintCancer Biology